Gock Hilton, Murray-Segal Lisa, Salvaris Evelyn, Cowan Peter J, D'Apice Anthony J F
Transplantation. 2002 Sep 15;74(5):637-45. doi: 10.1097/00007890-200209150-00009.
Elimination of galactose-alpha1,3-galactose (Gal), the major xenoantigen between pig and human, may extend pig-to-human xenograft survival beyond the current barrier of acute vascular rejection. However, it has been suggested that Gal is an essential molecule in the pig and that the generation of a Gal-deleted (Gal KO) pig will not be possible. Should this be the case, understanding the Gal-mediated immune response will be crucial in developing strategies to overcome pig xenograft rejection in humans. There are no existing models of xenograft rejection in which the sole difference between donor and recipient is Gal. We describe a model of exclusively Gal-mismatched skin graft rejection.
The survival of Gal skin grafts on Gal KO mice with the same genetic background was analyzed. To examine innate anti-Gal immunity, Gal KO recipients that were also deficient in T and B cells (RAG-1 KO) were used. To study the role of cognate immunity, recipients were sensitized with a primary Gal allograft before receiving a second Gal graft that was otherwise isogeneic. To test the role of anti-Gal antibodies in this model, recipients were passively immunized with a non-complement-fixing anti-Gal monoclonal antibody.
Gal KO mice chronically reject Gal skin grafts by 100 days at a rate of 48% (n=25) on a BALB/c background and 25% (n=8) on a C57BL/6 background. The grafts had an infiltrate that consisted predominantly of CD4 T cells and macrophages, whereas recipients deficient in T and B cells were incapable of rejection and survived for more than 120 days (n=5). Sensitization with a primary Gal allograft increased the incidence and the tempo of rejection of a second Gal-only mismatched skin graft with 99% rejection that ranged from 11 to 45 days (n=26). Passive transfer of mouse IgG anti-Gal monoclonal-antibody-induced rejection in Gal KO and RAG-1/Gal double-KO recipients at a rate of 92% (n=13).
We have established a model to study rejection based solely on a Gal mismatch. Our results indicate that non-complement-fixing anti-Gal antibody can cause rejection in the acute vascular rejection time frame and that T-cell-mediated chronic rejection will be a further barrier to overcome if Gal cannot be deleted from the pig.
消除猪与人之间主要的异种抗原——半乳糖-α1,3-半乳糖(Gal),可能会使猪到人的异种移植存活时间延长,突破当前急性血管排斥的障碍。然而,有人提出Gal是猪体内的一种必需分子,不可能培育出缺失Gal(Gal基因敲除,Gal KO)的猪。如果真是这样,那么了解Gal介导的免疫反应对于制定克服人类异种移植排斥的策略至关重要。目前尚无供体与受体之间唯一差异为Gal的异种移植排斥模型。我们描述了一种仅Gal不匹配的皮肤移植排斥模型。
分析了具有相同遗传背景的Gal基因敲除小鼠上Gal皮肤移植的存活情况。为了检测先天性抗Gal免疫,使用了同时缺乏T细胞和B细胞(RAG-1基因敲除)的Gal基因敲除受体。为了研究同源免疫的作用,受体在接受第二次同基因Gal移植之前,先用初次Gal同种异体移植进行致敏。为了测试抗Gal抗体在该模型中的作用,用非补体结合抗Gal单克隆抗体对受体进行被动免疫。
Gal基因敲除小鼠在100天内会慢性排斥Gal皮肤移植,在BALB/c背景下排斥率为48%(n = 25),在C57BL/6背景下为25%(n = 8)。移植组织中有主要由CD4 T细胞和巨噬细胞组成的浸润,而缺乏T细胞和B细胞的受体无法排斥移植组织,存活超过120天(n = 5)。用初次Gal同种异体移植致敏会增加第二次仅Gal不匹配皮肤移植的排斥发生率和速度,排斥率达99%,排斥时间为11至45天(n = 26)。在Gal基因敲除和RAG-1/Gal双基因敲除受体中,小鼠IgG抗Gal单克隆抗体的被动转移诱导排斥的发生率为92%(n = 13)。
我们建立了一个仅基于Gal不匹配来研究排斥的模型。我们的结果表明,非补体结合抗Gal抗体可在急性血管排斥时间范围内引发排斥反应,并且如果无法从猪体内删除Gal,T细胞介导的慢性排斥将成为进一步需要克服的障碍。